WA
LCTX icon

Wealth Architects’s Lineage Cell Therapeutics LCTX Stock Holding History

Wealth Architects’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,100
Closed -$25K – 194
2022
Q1 		$25K Buy
+16,100
New +$25K ﹤0.01% 205
2021
Q3 		– Sell
-17,500
Closed -$50K – 191
2021
Q2 		$50K Sell
17,500
-18,500
-51% -$47.9K 0.01% 187
2021
Q1 		$85K Buy
36,000
+18,000
+100% +$43.2K 0.02% 164
2020
Q4 		$32K Buy
+18,000
New +$25.2K 0.01% 161

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wealth Architects's LCTX Position: Q2 2022 in Review

Wealth Architects sold out of Lineage Cell Therapeutics (LCTX) in Q2 2022, closing a stake of 16,100 shares — an estimated $25K sold.

Wealth Architects first reported a position in LCTX in Q4 2020 and held it in 4 quarters. The position peaked at $85K in Q1 2021. 101 funds tracked by Wall St. Rank hold LCTX as of Q2 2022.

  • Wealth Architects reported no remaining Lineage Cell Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Wealth Architects sold 16,100 Lineage Cell Therapeutics shares in Q2 2022, an estimated $25K.
  • Wealth Architects first reported a position in Lineage Cell Therapeutics in Q4 2020 and held it in 4 quarters.
  • Wealth Architects's Lineage Cell Therapeutics position peaked at $85K in Q1 2021.
  • 101 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2022.

Based on Wealth Architects's 13F filing for Q2 2022, filed 29 Jul 2022.